A novel RKAA-peptide linker technology creates a more stable CD79b-targeting antibody-drug conjugate than FDA-approved polatuzumab vedotin.
Improved stabilityRKAA-peptide linked ADC shows better circulatory stability than FDA-approved polatuzumab vedotin
What the researchers found
A novel RKAA-peptide linker creates a more stable CD79b-ADC than polatuzumab vedotin, potentially widening the therapeutic window.
Why it matters
Better ADC stability means less drug leaks into healthy tissue, potentially reducing severe side effects while maintaining cancer-killing power.
The numbers in context
Drug-to-antibody ratio of 2; equal efficacy at half payload dose vs polatuzumab vedotin; stable in mouse, cynomolgus, and human sera.
How the study worked
Preclinical comparison of RKAA-peptide linked ADC vs. FDA-approved polatuzumab vedotin for stability, efficacy, and safety.
Who was studied
N/A (cancer cell lines and mouse xenograft models)
What this study cannot tell us
Preclinical study — human clinical trial data needed to confirm safety and efficacy advantages.
How to read the evidence
Preclinical comparison study — demonstrates improved pharmacological properties but requires clinical validation.
When this study was published
Published in 2025, advancing next-generation ADC technology.
The bigger picture
Next-generation ADC linker technologies could make targeted cancer therapy both more effective and less toxic.
Questions still open
- Can the RKAA linker be applied to other ADC targets beyond CD79b?
- Does improved stability translate to better clinical outcomes?
Common questions
What is an antibody-drug conjugate?
Why does the linker matter in ADCs?
Read the original research
Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC.
Molecular cancer therapeutics, 24(6), 803-815
Citation
Probst, Philipp; Attinger-Toller, Isabella; Bertrand, Romain; Stark, Ramona; Santimaria, Roger; Schlereth, Bernd; Grabulovski, Dragan; Spycher, Philipp René. (2025). Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC.. Molecular cancer therapeutics, 24(6), 803-815. https://doi.org/10.1158/1535-7163.MCT-24-0983